Kenneth Young

Title: Kenneth Young: Innovator in Antibody Research

Introduction

Kenneth Young is a prominent inventor based in Hamburg, Germany. He has made significant contributions to the field of antibody research, particularly focusing on Semaphorin 3A. With a total of 2 patents, his work has the potential to impact various therapeutic applications.

Latest Patents

Kenneth Young's latest patents include innovative developments in anti-Semaphorin 3A antibodies. The first patent discloses an isolated antibody or antigen-binding fragment that specifically binds to human Semaphorin 3A (Sema3A). This patent also includes an antibody conjugate and a pharmaceutical composition that utilizes this isolated antibody. The second patent further elaborates on anti-Sema3A antibodies, detailing their binding characteristics and inhibitory effects on human Sema3A activity in various assays. These advancements highlight the potential for targeted therapies in treating conditions related to Sema3A.

Career Highlights

Kenneth Young is currently employed at Bayer Aktiengesellschaft, where he continues to advance his research in antibody development. His work is characterized by a strong focus on the therapeutic applications of his inventions, particularly in the context of human health.

Collaborations

Kenneth collaborates with notable colleagues, including Dorian Schönfeld and Karoline Dröbner. Their combined expertise contributes to the innovative research environment at Bayer.

Conclusion

Kenneth Young's contributions to antibody research, particularly in the area of Semaphorin 3A, demonstrate his commitment to advancing medical science. His patents reflect a dedication to developing targeted therapies that could significantly benefit patients in the future.